[5-fluoro-1-(4-isopropylbenzylidene)-2-methylinden-3-yl]acetic-acid and Breast-Neoplasms

Nuclear receptor RXRα plays an important role in many biological and pathological processes. The nongenomic action of RXRα is implicated in many cancers. K-8008, a non-canonical RXRα ligand derived from sulindac, inhibits the TNFα-activated PI3K/AKT pathway by mediating the interaction between a truncated form of RXRα (tRXRα) and the p85α regulatory subunit of PI3K and exerts potent anticancer activity in animal model. Herein we report our studies of a novel series of K-8008 analogs as potential anticancer agents targeting RXRα. Two compounds 8b and 18a were identified to have slightly stronger binding to RXRα and improved apoptotic activities in breast cancer cells.

Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Design; Humans; Ligands; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Retinoid X Receptor alpha; Tetrazoles; Tumor Necrosis Factor-alpha